...
首页> 外文期刊>Cardiovascular drugs and therapy >How to mediate cardioprotection in ischemic hearts--accumulated evidence of basic research should translate to clinical medicine.
【24h】

How to mediate cardioprotection in ischemic hearts--accumulated evidence of basic research should translate to clinical medicine.

机译:如何介导缺血性心脏的心脏保护-基础研究的累积证据应转化为临床医学。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Ischemic heart failure is one of the leading causes of death in the western countries and it is a critical issue to overcome ischemic heart diseases for the human health care worldwide. There are several aspects of ischemic heart failure that we need to seriously consider for the conquest of cardiovascular death. First of all, we need to know either causes or pathophysiology of the onset of coronary artery disease, the ischemia/reperfusion injury and post-infarction cardiac remodeling. Secondly, we need to find the potential seeds for the molecular, pharmacological, biomedical or engineering treatment to prevent or attenuate ischemic heart diseases. Thirdly, we need to accelerate translational research and to create the network of clinical trials to grow the novel seeds to the fruitful big trees. Finally, we need to justify these strategies to overcome the ischemic heart diseases and to contribute the world welfare systems after we propose the novel therapy for the prevention and attenuation of ischemic heart diseases. The most strong and essential hypotheses to attenuate the cardiovascular injury in ischemic heart disease for last three decades are ischemic preconditioning/postconditioning. Many investigators have involved in the clarification of the characteristics of ischemic preconditioning/postconditioning and their cellular mechanisms, and the clinical applications of their basic results. Here, 8 potential basic and clinical researchers includeing us discuss these issues that they have devotedly studies for many years.
机译:缺血性心力衰竭是西方国家的主要死亡原因之一,它是克服缺血性心脏病的关键问题,对全世界的人类医疗保健而言。缺血性心力衰竭有几个方面需要我们认真考虑,以征服心血管死亡。首先,我们需要了解冠状动脉疾病,缺血/再灌注损伤和梗死后心脏重塑的起因或病理生理。其次,我们需要寻找用于预防或减轻缺血性心脏病的分子,药理,生物医学或工程学治疗的潜在种子。第三,我们需要加速转化研究,并建立临床试验网络,以将新型种子种植到硕果累累的大树上。最后,在我们提出预防和减轻缺血性心脏病的新疗法之后,我们需要证明这些策略以克服缺血性心脏病并为世界福利体系做出贡献。在过去的三十年中,减轻缺血性心脏病心血管损伤的最强有力且最基本的假设是缺血预处理/后处理。许多研究者参与了缺血预适应/后适应特征及其细胞机制的澄清,以及其基本结果的临床应用。在这里,包括我们在内的8位潜在的基础和临床研究人员讨论了他们多年来致力于研究的这些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号